Document Detail


Epidermal growth-factor receptors and erbb2 protein expression in esophageal cancer and normal mucosa.
MedLine Citation:
PMID:  21597745     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The epidermal growth factor receptor (EGFr) and the erbB2 protein (p185) concentrations were assessed in 31 esophageal cancer specimens and in the corresponding normal mucosa, in order to investigate the possible links with the main clinical and pathological parameters. Detectable and high affinity EGFr was found in 27/31 cancer and in 18/31 normal tissue samples. EGFr concentrations were not significantly different between cancer and normal tissue, although a trend toward higher levels in cancer was found. No relationships were found with histologic type, tumor bulk, lymph node status, pathologic stage, ploidy and type of surgical resection. A significant negative correlation between EGFr levels and overall survival was found. Detectable levels of p185 were found in all the tissues examined, but the expression was higher in adenocarcinoma than in squamous cell carcinoma samples. The EGFr role in malignant transformation still has to be established, but the determination could be of clinical use. As for p185, its role in the onset of esophageal cancer could be confined to the subgroup of the adenocarcinomas.
Authors:
R Dittadi; A Ruol; M Gion; A Segalin; M Panozzo; A Brazzale; S Meo; E Ancona; A Peracchia
Related Documents :
22120005 - What factors affect the odds of nsw cancer patients presenting with localised as oppose...
21945565 - Membrane-active host defense peptides--challenges and perspectives for the development ...
25466495 - Vitamin e transporters in cancer therapy.
21993845 - Anti-angiogenic agents in ovarian cancer: dawn of a new era?
23024545 - Metachronous colorectal malignancies.
22265435 - American brachytherapy society consensus guidelines for high-dose-rate prostate brachyt...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Oncology reports     Volume:  2     ISSN:  1021-335X     ISO Abbreviation:  Oncol. Rep.     Publication Date:  1995 May 
Date Detail:
Created Date:  2011-05-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9422756     Medline TA:  Oncol Rep     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  381-5     Citation Subset:  -    
Affiliation:
GEN HOSP,CTR STUDY BIOL MARKERS MALIGNANCY,I-30122 VENICE,ITALY. UNIV PADUA,DEPT GEN SURG 2,I-35100 PADUA,ITALY. UNIV MILAN,DEPT GEN SURG & SURG ONCOL,I-20100 MILAN,ITALY. UNIV PADUA,INST ONCOL,IST,BIOTECNOL SECT,I-35100 PADUA,ITALY.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Weekly 24-hour infusion with high-dose 5-Fluorouracil and 6s-leucovorin as a 2nd-line therapy in adv...
Next Document:  Modulation of the response of a rodent fibrosarcoma to photodynamic therapy by hyperbaric-oxygen tre...